Intra-cellular therapies reports first quarter 2023 financial results and provides corporate update

Q1 2023 total revenues of $95.3 million, compared to $35.0 million in the same period in 2022 caplyta q1 2023 net product sales were $94.7 million, compared to $34.8 million for the same period in 2022, representing a 173% increase q1 2023 caplyta total prescriptions increased 159%, versus the same period in 2022 and 16% sequentially versus q4 2022 reiterating caplyta 2023 net product sales guidance of $430 to $455 million announced robust positive results from study 403 in patients with mixed features in major depressive disorder (mdd) and mixed features in bipolar depression new york, may 04, 2023 (globe newswire) -- intra-cellular therapies, inc. (nasdaq: itci), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (cns) disorders, today announced its financial results for the first quarter ended march 31, 2023 and provided a corporate update. “we are pleased with the progress we have made in the first quarter and we are confident in the continued growth of caplyta,” said dr. sharon mates, chairman and ceo of intra-cellular therapies.
ITCI Ratings Summary
ITCI Quant Ranking